ArticleAmerican journal of translational research2026
Vitamin D +Docosahexaenoic acid supplementation: effects on serum markers and symptoms in ADHD children.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect of vitamin D combined with Docosahexaenoic acid (DHA) supplementation on serum indicators, clinical symptoms and disease severity in children with attention deficit hyperactivity disorder (ADHD), and identify independent risk factors for treatment efficacy.
methodsA retrospective analysis was performed on 367 children with ADHD admitted from August 2020 to August 2024, divided into control group (routine behavioral education + atomoxetine hydrochloride, n=180) and nutritional intervention (NI) group (additional vitamin D + DHA, n=187). The sample was split into training set (n=256) and validation set (n=111) at a 7:3 ratio, with relevant indicators analyzed via logistic regression, nomogram and ROC curve.
resultsAfter 3 months of treatment, the NI group had significantly lower ADHD Rating Scale IV (ADHD-RS-IV) and Clinical Global Impression Scale-Severity (CGI-S) scores, higher serum 25-hydroxyvitamin D [25(OH)D] and ferritin (SF) levels, higher total effective rate (94.49% vs 82.95%, P=0.004), and lower adverse reaction rate (4.72% vs 13.18%, P=0.018) than the control group (all P<0.05). Baseline ADHD-RS-IV≥26.5 points, CGI-S≥4.5 points, 25(OH)D<14.26 ng/mL and SF<19.61 ng/mL were independent risk factors for poor efficacy; their combined detection had an Area Under the Curve (AUC) of 0.901 in the validation set.
conclusionVitamin D combined with DHA can improve clinical symptoms, serum nutritional indicators, efficacy and safety of ADHD children. The 4 indicators are key factors affecting efficacy, and their combined detection has more accurate diagnostic efficiency.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.